<DOC>
	<DOCNO>NCT00987337</DOCNO>
	<brief_summary>The primary objective study determine addition filibuvir standard regimen peginterferon/ribavirin ( pegIFN/RBV ) significantly increase proportion subject achieve sustain viral response ( SVR ) compare peginterferon/ribavirin ( pegIFN/RBV ) therapy alone .</brief_summary>
	<brief_title>Filibuvir In Treatment Naive Hepatitis C Virus ( HCV ) Genotype 1 Subjects</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<criteria>Male female subject least 18 year age . HCV seropositive . HCV RNA &gt; 10,000 IU/mL screening . HCV Genotype 1 . Subjects infect nongenotype 1 strain mixed genotype eligible . Treatment na√Øve ( prior treatment IFN alfa +/ RBV regimens investigational antiHCV agent ) . Liver biopsy within two year ( 24 month ) Screening noncirrhotic fibrosis classification . For subject liver biopsy outside time window subject history liver biopsy , biopsy must perform prior randomization . Ultrasound within 6 month Screening 1 ) subject bridge fibrosis 2 ) subject AFP &gt; 50 &lt; 100 ng/mL evidence hepatocellular carcinoma . For subject ultrasound conduct outside 6month time window , ultrasound must perform prior randomization . Coinfection either HIV HBV . Evidence severe decompensated liver disease . Subjects liver disease unrelated HCV infection . Preexisting medical condition make subject unsuitable treatment pegIFN/RBV therapy per product labeling . Laboratory abnormality Screening make subject unsuitable treatment pegIFN/RBV therapy per product labeling . Abnormal ECG suggestive clinically significant cardiac disease QTc &gt; 450msec . History organ transplant . Contraindicated medication take subject time randomization must continue study period , include potent CYP3A4 inhibitor , sensitive CYP3A4 substrate , CYP3A4 substrates narrow therapeutic range CYP3A4 inducer . Active alcohol substance abuse sufficient , Investigator 's judgment , prevent adherence study medication and/or follow . Pregnant nursing female . Males whose female partner pregnant .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>Hepatitis C Polymerase Inhibitor PF-00868554 Filibuvir</keyword>
</DOC>